A5100704933- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Endometrial and Cervical Cancer Treatments
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Testicular diseases and treatments
- Cervical Cancer and HPV Research
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Renal cell carcinoma treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Lung Cancer Treatments and Mutations
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Research Studies
- HIV/AIDS drug development and treatment
- Cancer Genomics and Diagnostics
All India Institute of Medical Sciences
2016-2025
Artemis Hospitals
2023-2025
National Institute of Pharmaceutical Education and Research
2025
DR. B.R.A. Institute Rotary Cancer Hospital
2014-2024
Beam Therapeutics (United States)
2024
Indira Gandhi Mirpur University
2022-2024
Midnapore Medical College and Hospital
2024
Institute of Medical Sciences
2016-2023
University Health Care System
2023
Babasaheb Bhimrao Ambedkar University
2022-2023
Abstract The Gynecologic Oncology Committee of FIGO in 2014 revised the staging ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into same system. Most these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on tube surface); IC3 (malignant cells ascites washings). updated includes a revision IIIC based spread to retroperitoneal lymph nodes alone...
The rising economic burden of cancer on patients is an important determinant access to treatment initiation and adherence in India. Several publicly financed health insurance (PFHI) schemes have been launched India, with for as explicit inclusion the benefit packages (HBPs). Although, financial toxicity widely acknowledged be a potential consequence costly treatment, little known about its prevalence determinants among Indian population. There need determine optimal strategy clinicians care...
Abstract Background Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well adverse effects therapy. We evaluated HRQoL cancer patients, stratified by primary site, stage, treatment response and associated events, along with its determinants. Methods Data were collected 12,148 sampled seven purposively chosen leading hospitals India, to elicit using EuroQol questionnaire comprising 5-dimensions 5-levels (EQ-5D-5L). Multiple linear...
Abstract There are disparities in outcomes for patients with multiple myeloma (MM). We evaluated the influence of sociodemographic factors on global MM. This rapid evidence assessment (PROSPERO, CRD42021248461) followed PRISMA-P guidelines and used PICOS framework. PubMed Embase® were searched articles English from 2011 to 2021. The title, abstract, full text screened according inclusion/exclusion criteria. assessed age, sex, race/ethnicity, socioeconomic status, geographic location....
BackgroundOral mucositis is a common inflammatory complication in patients undergoing high-dose chemotherapy and radiation followed by haematopoietic stem cell transplantation (HSCT). Lactobacillus brevis CD2 has been proven efficacious preventing chemoradiotherapy-induced oral squamous carcinoma of head neck.MethodsThis phase II study aimed to evaluate the safety efficacy L. lozenges HSCT. Eligible received four six per day, beginning from 4 7 days before initiation continuing until...
The genes related to B-cell development are frequently altered in acute lymphoblastic leukemia (B-ALL). One hundred sixty-two newly diagnosed B-ALL cases, median age 8.5 years (2 months–67 years), were prospectively analyzed for copy number alterations (CNAs) CDKN2A/B, IKZF1, PAX5, RB1, ETV6, BTG1, EBF1, and pseudoautosomal region (CRLF2, CSF2RA, IL3RA) using multiplex ligation-dependent probe amplification. CNAs detected 114 (70.4%) cases; most commonly affected being CDKN2A/B-55 (34%),...